Biomerica (BMRA) 10-K 31 Aug 20 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	May 31, 2020	Aug. 31, 2020	Nov. 30, 2019
Document Information Line Items
Entity Registrant Name	BIOMERICA INC
Document Type	10-K
Current Fiscal Year End Date	--05-31
Entity Common Stock, Shares Outstanding		11,752,589
Entity Public Float			$ 23,397,870
Amendment Flag	false
Entity Central Index Key	0000073290
Entity Current Reporting Status	Yes
Entity Voluntary Filers	Yes
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	May 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	May 31, 2020	May 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 8,641,027	$ 686,785
Accounts receivable, less allowance for doubtful accounts of $70,981 and $73,110, respectively	1,765,871	1,454,652
Inventories, net	2,850,836	2,151,090
Prepaid expenses and other	1,509,083	202,402
Total current assets	14,766,817	4,494,929
PROPERTY AND EQUIPMENT:
Equipment	1,921,833	1,891,381
Furniture, fixtures and leasehold improvements	225,189	222,033
Total property and equipment	2,147,022	2,113,414
Accumulated depreciation	(1,867,643)	(1,762,344)
Net property and equipment	279,379	351,070
INTANGIBLE ASSETS, net of accumulated amortization	168,655	107,209
RIGHT OF USE ASSETS, net of accumulated amortization	1,711,510
INVESTMENTS	165,324	165,324
OTHER ASSETS	168,193	126,832
TOTAL ASSETS	17,259,878	5,245,364
CURRENT LIABILITIES:
Accounts payable and accrued expenses	986,711	1,037,565
Accrued compensation	278,627	226,829
Lease liability, current portion	211,809
Total current liabilities	1,477,147	1,264,394
Lease liability, net of current portion	1,569,678
Total liabilities	3,046,825	1,264,394
COMMITMENTS AND CONTINGENCIES (NOTE 8)
SHAREHOLDERS' EQUITY:
Preferred stock, Series A 5%, convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at May 31, 2020 and no shares authorized, issued and outstanding at May 31, 2019 and Preferred stock, undesignated, no par value, authorized 4,428,571 and 5,000,000 shares, at May 31, 2020 and May 31, 2019, respectively and none issued and outstanding at May 31, 2020 and May 31, 2019	25,714
Common stock, $.08 par value; 25,000,000 shares authorized; 11,740,089 and 9,677,188 shares issued and outstanding at May 31, 2020 and 2019, respectively	939,205	774,173
Additional paid-in capital	35,213,707	22,830,006
Accumulated other comprehensive loss	(39,841)	(36,531)
Accumulated deficit	(21,925,732)	(19,586,678)
Total shareholders' equity	14,213,053	3,980,970
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	17,259,878	5,245,364
5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]
SHAREHOLDERS' EQUITY:
Preferred stock, Series A 5%, convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at May 31, 2020 and no shares authorized, issued and outstanding at May 31, 2019 and Preferred stock, undesignated, no par value, authorized 4,428,571 and 5,000,000 shares, at May 31, 2020 and May 31, 2019, respectively and none issued and outstanding at May 31, 2020 and May 31, 2019	25,714
Preferred Stock [Member]
SHAREHOLDERS' EQUITY:
Preferred stock, Series A 5%, convertible, $0.08 par value, 571,429 shares authorized, 321,429 issued and outstanding at May 31, 2020 and no shares authorized, issued and outstanding at May 31, 2019 and Preferred stock, undesignated, no par value, authorized 4,428,571 and 5,000,000 shares, at May 31, 2020 and May 31, 2019, respectively and none issued and outstanding at May 31, 2020 and May 31, 2019

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	May 31, 2020	May 31, 2019
Allowance for doubtful accounts (in Dollars)	$ 70,981	$ 73,110
Common stock par value (in Dollars per share)	$ 0.08	$ 0.08
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	11,740,089	9,677,188
Common stock, shares outstanding	11,740,089	9,677,188
5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]
Preferred Stock, Par Value (in Dollars per share)	$ 0.08
Preferred Stock, shares authorized	571,429
Preferred Stock, shares issued	321,429
Preferred Stock, shares outstanding	321,429
Preferred Stock [Member]
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Preferred Stock, No Par Value (in Dollars per share)	$ 0	$ 0
Preferred Stock, undesignated shares	4,428,571	5,000,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	May 31, 2020	May 31, 2019
Income Statement [Abstract]
Net sales	$ 6,692,711	$ 5,200,682
Cost of sales	(4,910,935)	(3,908,668)
GROSS PROFIT	1,781,776	1,292,014
OPERATING EXPENSES:
Selling, general and administrative	2,274,415	2,025,706
Research and development	1,910,209	1,679,098
Total operating expenses	4,184,624	3,704,804
LOSS FROM OPERATIONS	(2,402,848)	(2,412,790)
OTHER INCOME (EXPENSE):
Interest expense	(9)	(47)
Interest and dividend income	71,193	44,014
Total other income	71,184	43,967
LOSS BEFORE INCOME TAXES	(2,331,664)	(2,368,823)
INCOME TAX EXPENSE	(7,390)	(24,237)
NET LOSS	$ (2,339,054)	$ (2,393,060)
BASIC NET LOSS PER COMMON SHARE (in Dollars per share)	$ (0.23)	$ (0.26)
DILUTED NET LOSS PER COMMON SHARE (in Dollars per share)	$ (0.23)	$ (0.26)
WEIGHTED AVERAGE NUMBER OF COMMON AND COMMON EQUIVALENT SHARES
Basic (in Shares)	10,166,296	9,212,557
Diluted (in Shares)	10,166,296	9,212,557
NET LOSS	$ (2,339,054)	$ (2,393,060)
OTHER COMPREHENSIVE LOSS:
Foreign currency translation	(3,310)	(10,395)
COMPREHENSIVE LOSS	$ (2,342,364)	$ (2,403,455)

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS` EQUITY - USD ($)	Series A Preferred Stock [Member]5% Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscriptions Receivable [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balances at May. 31, 2018		$ 711,040	$ 20,843,550	$ (9,062)	$ (26,136)	$ (17,193,618)	$ 4,325,774
Balances (in Shares) at May. 31, 2018		8,888,011
Exercise of stock options		$ 13,080	108,710				121,790
Exercise of stock options (in Shares)		163,500
Net proceeds from ATM		$ 50,053	1,726,522				1,776,575
Net proceeds from ATM (in Shares)		625,677
Stock subscription receivable				$ 9,062			9,062
Foreign currency translation					(10,395)		(10,395)
Compensation expense in connection with options granted			151,224				151,224
Net loss						(2,393,060)	(2,393,060)
Balances at May. 31, 2019		$ 774,173	22,830,006		(36,531)	(19,586,678)	3,980,970
Balances (in Shares) at May. 31, 2019		9,677,188
Exercise of stock options		$ 11,037	212,497				223,534
Exercise of stock options (in Shares)		137,958
Net proceeds from ATM		$ 133,995	10,098,862				10,232,857
Net proceeds from ATM (in Shares)		1,674,943
Issuance of preferred stock	$ 45,714		1,871,872				1,917,586
Issuance of preferred stock (in Shares)	571,429
Foreign currency translation					(3,310)		(3,310)
Conversion of preferred to common stock	$ (20,000)	$ 20,000
Conversion of preferred to common stock (in Shares)	(250,000)	250,000
Compensation expense in connection with options granted			200,470				200,470
Net loss						(2,339,054)	(2,339,054)
Balances at May. 31, 2020	$ 25,714	$ 939,205	$ 35,213,707		$ (39,841)	$ (21,925,732)	$ 14,213,053
Balances (in Shares) at May. 31, 2020	321,429	11,740,089

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	May 31, 2020	May 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,339,054)	$ (2,393,060)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	129,172	162,905
Change in provision for allowance for doubtful accounts	(2,129)	15,415
Inventory reserve	17,714	6,300
Stock option expense	200,470	151,224
Reduction (increase) in deferred rent liability	(37,971)	6,615
Decrease in deferred tax asset		10,000
Amortization of right-of-use asset	269,460
Changes in assets and liabilities:
Accounts receivable	(309,090)	(670,126)
Inventories	(717,460)	21,387
Prepaid expenses and other	(1,306,681)	98,007
Reduction in lease liability	(199,483)
Other assets	(41,361)	(13,677)
Accounts payable and accrued expenses	(12,883)	343,994
Accrued compensation	51,798	16,977
Net cash used in operating activities	(4,297,498)	(2,244,039)
CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in intangibles	(85,319)	(69,974)
Purchases of property and equipment	(33,608)	(101,137)
Net cash used in investing activities	(118,927)	(171,111)
CASH FLOWS FROM FINANCING ACTIVITIES:
Common stock subscribed		9,062
Proceeds from sale of convertible preferred stock, net	1,917,586
Proceeds from sales of common stock, net	10,232,857	1,776,575
Proceeds from exercise of stock options	223,534	121,790
Net cash provided by financing activities	12,373,977	1,907,427
Effect of exchange rate changes on cash	(3,310)	(10,395)
Net increase (decrease) in cash and cash equivalents	7,954,242	(518,118)
CASH AND CASH EQUIVALENTS, beginning of year	686,785	1,204,903
CASH AND CASH EQUIVALENTS, end of year	8,641,027	686,785
Cash paid during the year for:
Interest	9	47
Income taxes	7,390	14,237
Non-cash Investing and Financing Activities:
Establishment of Right-of-use asset per ASC 842	1,942,999
Establishment of Lease liability per ASC 842	$ 1,980,970

ORGANIZATION

ORGANIZATION	12 Months Ended
	May 31, 2020
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. ORGANIZATION Biomerica Inc. and Subsidiaries (collectively the “Company”, “we”, “us”, or “our”) develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians' offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. Our diagnostic test kits are used to analyze blood, urine or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Our primary focus is the research and development of revolutionary, patented diagnostic guided therapy (“DGT”) products to treat gastrointestinal diseases, such as irritable bowel syndrome, and other inflammatory diseases. These products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. If these DGT products prove effective in their clinical trials, and are ultimately cleared for sale by the U.S. Food and Drug Administrations (“FDA”), the revenues potential to the Company is significant. Due to the global 2019 SARS-CoV-2 novel coronavirus (“COVID-19”) pandemic, in March 2020 we began redirecting and focused a majority of our resources to develop, test, validate, seek regulatory approval for, and sell diagnostic products that indicate if a person has been exposed to COVID-19.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	May 31, 2020
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES PRINCIPLES OF CONSOLIDATION The enclosed consolidated financial statements for the years ended May 31, 2020 and 2019 include the accounts of Biomerica, Inc. ("Biomerica") as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation. ACCOUNTING ESTIMATES The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; and inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based). Actual results could materially differ from those estimates. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable, and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values. CONCENTRATION OF CREDIT RISK The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. As of May 31, 2020, the Company had approximately $8,595,241 of uninsured cash. The Company does not believe it is exposed to any significant credit risks. The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets. The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. For the years ended May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 57.2% and 46.3% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2020 and 2019 one of the distributors mentioned above accounted for 25.7% and 36.3%, respectively, of net consolidated sales. At May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 80.0% and 68.1%, respectively, of gross accounts receivable. Of the 80.0% as of May 31, 2020, 43.9% was owed by a distributor in Ecuador. Total gross receivables at May 31, 2020 and 2019 were $1,836,852 and $1,527,762, respectively. For the year ended May 31, 2020, one vendor accounted for 59.3% of the purchases of raw materials. For the year ended May 31, 2019, two vendors accounted for a total of 23.8 % of the purchases of raw materials. GEOGRAPHIC CONCENTRATION As of May 31, 2020 and 2019, approximately $613,000 and $665,000 of Biomerica's gross inventory and approximately $31,000 and $39,000, of Biomerica's property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively. CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months. ACCOUNTS RECEIVABLE The Company extends unsecured credit to its customers on a regular basis. International accounts are required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria, initial credit levels for individual distributors are approved by designated officers and managers of the company. All increases in credit limits are also approved by designated upper level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. Balances over ninety days old are usually reserved for unless collection is reasonably assured. Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders. INVENTORIES The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. Inventories approximate the following at May 31: 2020 2019 Raw materials $ 1,635,000 $ 1,208,000 Work in progress 988,000 771,000 Finished products 228,000 172,000 Total $ 2,851,000 $ 2,151,000 Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2020 and 2019, inventory reserves were approximately $67,000 and $49,000, respectively. PROPERTY AND EQUIPMENT Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $105,299 and $101,216 for the years ended May 31, 2020 and 2019, respectively. INTANGIBLE ASSETS Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (“ASC”), ASC 350 Intangibles – Goodwill and Other (“ASC 350”). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $23,873 and $61,689 for the years ended May 31, 2020 and 2019, respectively. The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2020 or 2019. INVESTMENTS From time-to-time, the Company makes investments in privately-held companies. The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received. SHARE-BASED COMPENSATION The Company follows the guidance of the accounting provisions of ASC 718 , The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. In applying the Black-Scholes options-pricing model, assumptions used were as follows: 2020 2019 Dividend yield 0% 0% Expected volatility 55.52-72.62% 57.90-60.41% Risk free interest rate 0.43-1.80% 2.33-2.85% Expected life 3.75-6.25 years 3.75-6.25 years REVENUE RECOGNITION The Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods. Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. Physicians’ office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. Disaggregation of revenue: The following is a breakdown of revenues according to markets to which the products are sold: Year Ended May 31, 2020 May 31, 2019 Clinical Lab $ 2,922,425 $ 4,043,993 OTC 1,269,535 868,605 Physicians’ Office 2,194,991 170,871 Contract Manufacturing 305,760 117,213 Total $ 6,692,711 $ 5,200,682 See Note 7 for additional information regarding revenue concentrations. SHIPPING AND HANDLING FEES The Company includes shipping and handling fees billed to customers in net sales. RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The Company expensed $1,910,209 and $1,679,098 of research and development costs during the years ended May 31, 2020 and 2019, respectively. INCOME TAXES The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2020 and 2019, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets. During the fiscal year ended May 31, 2020, this valuation allowance was increased to approximately $ 3,175,000, which fully covers the net tax asset of $3,175,000 . The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company’s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the “Interest expense” line and penalties related to liabilities for income taxes within the “Other expense” line of the consolidated statements of operations and comprehensive loss. ADVERTISING COSTS The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately $174 FOREIGN CURRENCY TRANSLATION The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2020 and 2019. RIGHT-OF-USE ASSETS AND LEASE LIABILITY Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. During the year ended May 31, 2020, the Company adopted ASC 842, Leases. As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time. In February 2016, the Financial Accounting Standards Board (“FASB”) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. Leases will be classified as financing or operating which will drive the expense recognition pattern. For lessees, the statement of operations presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively. The Company has elected to exclude short-term leases. The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method. As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. Both will be amortized over the life of the underlying leases. For additional information, see Note 8-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term. NET LOSS PER SHARE Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2020 and 2019 were 1,789,251 and 1,476,209, respectively. The Company also has outstanding 321,429 of Series A 5% Convertible Preferred Stock, which may be converted at any time to common stock. SEGMENT REPORTING ASC 280, Segment Reporting (“ASC 280”), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company’s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits. REPORTING COMPREHENSIVE LOSS Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders’ equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments. RECENT ACCOUNTING PRONOUNCEMENTS On February 15, 2018, the FASB issued ASU 2018-02, “Reclassification of Certain Tax Effects From Accumulated Comprehensive Income” (“ASU 2018-02”). ASU 2018-02 will give companies the option to reclassify stranded tax effects caused by the newly-enacted U.S. Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income (“ASCI”) to retained earnings. ASU 2018-02 was effective for all companies for the fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Management is taking the provisions of this statement into account in the preparation of the consolidated financial statements for the year ended May 31, 2020. The adoption of this standard has not had a significant impact on the Company’s consolidated financial statements. On June 20, 2018, the FASB issued ASU 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (service providers, external legal counsel, and suppliers). ASU 2018-07 was effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. During the year ended May 31, 2020, the Company adopted the provisions of this statement and is taking them into account in the preparation of the consolidated financial statements for the year ended May 31, 2020. The adoption of this standard has not had a significant impact on the Company’s consolidated financial statements. Other recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (“SEC”) did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.

INTANGIBLE ASSETS, NET

INTANGIBLE ASSETS, NET	12 Months Ended
	May 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	3. INTANGIBLE ASSETS, NET Intangible assets, net of accumulated amortization, consist of the following at May 31: 2020 2019 Licenses $ 551,397 $ 510,600 Patents 113,382 68,860 Less accumulated amortization- (487,989) (471,530) Less accumulated amortization- (8,135) (721) Intangible assets, net $ 168,655 $ 107,209 Expected amortization of intangible assets for the years ending May 31: 2021 $ 18,112 2022 8,503 2023 6,211 2024 6,136 2025 5,219 Thereafter 124,474 Total $ 168,655

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	May 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES The Company’s accounts payable and accrued expense balances consist of the following at May 31: 2020 2019 Accounts payable and accrued expenses $ 986,711 $ 999,594 Deferred rent - 37,971 $ 986,711 $ 1,037,565 As of May 31, 2020 and 2019 the Company had two vendors and one vendor which accounted for 26.9% and 32.1%, respectively, of accounts payable.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	May 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	5. SHAREHOLDERS' EQUITY On February 24, 2020, the Company filed with the Secretary of State of Delaware a certificate of designation to authorize for issuance 571,429 shares of Series A 5% Convertible Preferred Stock. On February 26, 2020, the Company filed with the Secretary of State of Delaware a certificate of correction, correcting certain language defects in the previously filed certificate of designation. Please see below a description of the Series A 5% Convertible Preferred Stock shares that were issued in February 2020. STOCK OPTION AND RESTRICTED STOCK PLANS In August 2010, the Company adopted a stock option and restricted stock plan (the "2010 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2010. The 2010 Plan expires in December 2020. Options granted under the 2010 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant. In December 2014, the Company adopted a stock option and restricted stock plan (the "2014 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2014. The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant. In December 2017, the Company adopted a stock option and restricted stock plan (the “2017 Plan”) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company’s unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2017. The 2017 Plan expires in December 2027. Options granted under the 2017 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant. In February 2020, the Board approved the 2020 Stock Incentive Plan (the “2020 Plan”), which will be presented to the Company’s shareholders for final approval and adoption at the Company’s annual meeting to be held in December 2020. The 2020 Plan authorizes the issuance of an aggregate number of common stock options and/or restricted common shares to be issued in an amount not to exceed 900,000. The 2020 Plan authorizes the issuance of common stock options and restricted common shares to employees, directors and consultants of the Company. During fiscal 2020, certain common stock options were granted under this plan, the actual vesting of which is subject to the plan being approved and adopted by shareholders at our upcoming annual meeting of shareholders. Stock option expense during fiscal 2020 was $200,470. This included, by department, $17,892 for research and development, $156,750 in administrative, $2,933 in sales and marketing, $22,895 for production and $0 in Mexico. In fiscal 2019, stock option expense was $151,224. This included $3,714 in research and development, $143,299 in administrative, $4,163 in sales and marketing and $48 in Mexico. Activity as to aggregate stock options outstanding is as follows: NUMBER OF STOCK OPTIONS EXERCISE PRICE RANGE PER SHARE WEIGHTED AVERAGE EXERCISE PRICE Options outstanding at May 31, 2018 1,138,625 $0.71-$3.90 $ 1.65 Options granted 558,000 $2.25-$3.62 $ 2.60 Options exercised (163,500) $0.71-$1.04 $ 0.76 Options canceled or expired (56,916) $0.71-$3.62 $ 2.49 Options outstanding at May 31, 2019 1,476,209 $0.82-$3.90 $ 2.07 Options granted 517,500 $2.68-$8.18 $ 4.47 Options exercised (137,958) $0.82-$3.90 $ 1.64 Options canceled or expired (66,500) $0.85-$8.18 $ 3.43 Options outstanding at May 31, 2020 1,789,251 $0.82-$8.18 $ 2.75 The weighted average fair value of options granted during 2020 and 2019 was $4.47 and $2.60, respectively. The aggregate intrinsic value of options exercised during 2020 and 2019 was approximately $589,000 and $364,000, respectively. The aggregate intrinsic value of options outstanding at May 31, 2020 and 2019 was approximately $6,923,000 and $808,000, respectively. The aggregate intrinsic value of options vested and exercisable at May 31, 2020 and 2019 was approximately $4,442,000 and $685,000, respectively. Number of non-vested stock options included in table above is as follows: NUMBER OF SHARES STOCK OPTIONS WEIGHTED AVERAGE AVERAGE GRANT DATE FAIR VALUE Non-vested shares at May 31, 2019 769,584 $ 2.49 Granted 517,500 $ 4.47 Vested (407,750) $ 2.25 Forfeited (56,750) $ 3.55 Non-vested shares at May 31, 2020 822,584 $ 3.78 At May 31, 2020, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $663,000. The weighted-average period over which this amount is expected to be recognized is 3.67 years. The weighted average remaining contractual term of options that were exercisable at May 31, 2020 was 6.19 years. The following summarizes information about all of the Company's stock options outstanding at May 31, 2020. These options are comprised of those granted under the 2010, 2014, 2017 and 2020 plans. RANGE OF EXERCISE PRICES NUMBER OUTSTANDING May 31, 2020 WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE IN YEARS WEIGHTED AVERAGE EXERCISE PRICE NUMBER EXERCISABLE AT MAY 31, 2020 WEIGHTED AVERAGE EXERCISE PRICE $ 0.82-$1.04 276,000 4.44 $0.84 276,000 $0.84 $ 1.20-$ 2.81 1,072,500 7.57 $2.17 506,000 $1.71 $ 3.62-$ 8.18 440,751 7.62 $5.38 184,667 $3.87 COMMON STOCK ACTIVITY During the year ended May 31, 2020, options to purchase 137,958 shares of common stock were exercised at prices ranging from $0.82 to $3.90. Total net proceeds to the Company were $223,534. During the year ended May 31, 2019, options to purchase 163,500 shares of common stock were exercised at prices ranging from $0.71 to $1.04. Total net proceeds to the Company were $121,790. On December 1, 2017, the Company entered into an At Market Issuance Sales Agreement (or “ATM Agreement”) with an agent, and filed a prospectus supplement with the SEC pursuant to which the Company could offer and sell from time to time up to an aggregate of $7,000,000 of shares of the Company’s common stock, par value $0.08 per share (the “Placement Shares”), through the agent. From December 1, 2017 to March 19, 2020, the Company sold common stock resulting in $6,997,935 of gross proceeds under this ATM Agreement, of which $3,771,048 were sold during the year ended May 31, 2020. This At Market Issuance Agreement expired on July 20, 2020 upon the expiration of the Company’s S-3 registration statement base prospectus dated July 20, 2017. The Placement Shares sold and issued under the ATM Agreement have been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Registration Statement on Form S-3 (File No. 333-219130) (the “Registration Statement”), which was originally filed with the SEC on June 30, 2017 and declared effective by the SEC on July 20, 2017, the base prospectus contained within the Registration Statement, and the prospectus supplement related to the sale of shares under the ATM Agreement was filed with the SEC on December 1, 2017. On March 20, 2020, the Company filed a new prospectus supplement to the S-3 registration statement base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the ATM Agreement. This ATM Agreement expired on July 20, 2020 upon the expiration of the Company’s S-3 registration statement base prospectus dated July 20, 2017. Gross proceeds for the year ended May 31, 2020, were $6,817,330. Please refer to “Subsequent Events” for a description of the Form S-3 filed with the Securities and Exchange Commission on July 20, 2020. Combined Placement Shares sold under the ATM during the twelve months ended May 31, 2020 under the two prospectus supplements dated December 1, 2017 and March 20, 2020 totaled 1,674,943 shares. Total net proceeds from the sale of Placement Shares under the two prospectus supplements during the twelve months ended May 31, 2020 were $10,232,857 after deducting commissions for each sale and legal, accounting, and other fees related to the filing of the Form S-3. These shares were sold at prices ranging from $2.33 to $9.08 per share. Under an ATM Agreement, sales of the Placement Shares are deemed to be “at the market offering” as defined in Rule 415 promulgated under the Securities Act. The agent acts as sales agent under the ATM and uses commercially reasonable efforts to sell on the Company’s behalf all of the Placement Shares requested to be sold from time to time by the Company, consistent with its normal trading and sales practices, on mutually agreed terms between the agent and the Company. The Company has no obligation to sell any of the Placement Shares under the ATM Agreement, and may at any time suspend offers under, or terminate the ATM Agreement. During the year ended May 31, 2020, 250,000 shares of common stock were converted from Preferred Stock as described below in “Preferred Stock Activity”. During the year ended May 31, 2020, the Company sold 1,674,943 shares of its common stock at prices ranging from $2.33 to $9.08 under its S-3 Registration Statement which resulted in gross proceeds of $10,588,378 and net proceeds to the Company of $10,232,857 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3. During the year ended May 31, 2019, the Company sold 625,677 shares of its common stock at prices ranging from $2.59 to $4.16 under its S-3 Registration Statement which resulted in gross proceeds of $1,847,662 and net proceeds to the Company of $1,776,575 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the Form S-3. PREFERRED STOCK ACTIVITY On February 24, 2020, the Company entered into and closed on a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Palm Global Small Cap Master Fund LP (“Palm”) pursuant to which the Company agreed to sell and issue to Palm, and Palm agreed to purchase from the Company, 571,429 shares of the Company’s Series A 5% Convertible Preferred Stock, $0.08 par value per share for a purchase price of approximately $2 million, or $3.50 per Series A Convertible Preferred Stock. Under the terms of the Stock Purchase Agreement, each share of issued Convertible Preferred Stock can be converted at any time by Palm into one share of the Company’s common stock, subject to certain adjustments. The Series A 5% Convertible Preferred Stock shares are convertible at the option of the holder at any time into an equal number of common stock shares (“Conversion Shares”). The conversion price may be adjusted for stock splits or other common stock issuances. The Company may require the conversion of all of the outstanding Series A 5% Convertible Preferred Stock shares if the closing sale price of the Company’s common stock equals or exceeds $9.00 for a period of five consecutive trading days with a minimum average trading volume of 35,000 shares per day over such period; provided, that, on such date, the Conversion Shares are registered for resale. The Series A 5% Convertible Preferred Stock shares accrue annual preferred dividends at a rate of $0.175 per Series A 5% Convertible Preferred Stock share. The shares of Series A 5% Convertible Preferred Stock are also entitled to receive participating dividends. The shares of Series A 5% Convertible Preferred Stock have no voting rights. Accruing dividends are payable only when, as, and if declared by the Board and the Company has no obligation to pay such accruing dividends. As such, since the dividend payment is conditional on events that are deemed unlikely at this time, a liability has not been recorded at year-end for these dividends. Dividends that have accumulated through May 31, 2020 total approximately $18,000. The 5% dividend is a cumulative dividend, and is only payable if the Board elects to pay a dividend on the Company’s common shares, at which point the accrued cumulative dividend must be paid current. At the conversion of any preferred shares into common shares, all accrued, unpaid dividends on the converted preferred shares are canceled and forgiven by Palm. As part of the purchase, Palm was given the right to appoint a Board Observer to the Board. The preferred shares have many material preferential rights over common shareholders in the event of a filing for bankruptcy or dissolution of the Company. For further details on the rights of these preferred shares, please refer to the Company’s disclosures filed under an SEC 8-K on February 26, 2020. On March 24, 2020, Palm converted 250,000 shares of Convertible Preferred Stock into 250,000 shares of unregistered common stock. On July 21, 2020, the Company filed with the SEC a registration statement on Form S-3 that among other things registered all of the common shares issued, or to be issued, to Palm upon conversion of the Convertible Preferred Stock into common shares. The Company anticipates the registration statement shall become effective promptly following the filing of this annual report on Form 10-K with the SEC. The Company incurred approximately $82,000 in issuance costs associated with this stock issuance.

INCOME TAXES

INCOME TAXES	12 Months Ended
	May 31, 2020
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	6. INCOME TAXES Income tax expense from continuing operations for the years ended May 31, 2020 and 2019 consists of the following: Years ended May 31, 2020 2019 Current: U.S. Federal $ -- $ -- Foreign Taxes Subsidiaries (6,590) (13,437) State and local (800) (800) Total current (7,390) (14,237) Deferred: U.S. Federal -- (10,000) State and local -- -- Total deferred -- (10,000) Income tax expense $ (7,390) $ (24,237) Income tax expense from continuing operations differs from the amounts computed by applying the U.S. Federal income tax rate applicable for each year (21% for 2020 and 2019) to pretax income as a result of the following: Years ended May 31, 2020 2019 Computed "expected" tax benefit $ 489,651 $ 497,453 Increase (reduction) in income taxes resulting from: Change in valuation allowance (716,000) (910,000) State income taxes, net of federal benefit 154,254 89,267 Research and development tax credits 49,770 55,908 Permanent tax differences and other 21,525 (256,572) Foreign taxes of subsidiaries (6,590) (13,437) Income tax expense $ (7,390) $ (24,237) The tax effect of significant temporary differences is presented below: As of May 31, 2020 2019 Deferred tax assets: Accounts receivable, principally due to allowance for doubtful accounts $ 17,000 $ 18,000 Inventory valuation 16,000 12,000 Compensated absences 64,000 48,000 Net operating loss carryforwards 2,286,000 1,735,000 Tax credit carryforwards 599,000 467,000 Deferred rent expense/Capitalized leases 17,000 9,000 Other 171,000 176,000 Accumulated depreciation and amortization 5,000 (6,000) Total deferred tax assets 3,175,000 2,459,000 Less valuation allowance (3,175,000) (2,459,000) Net deferred tax asset $ -- $ -- The Company has provided a valuation allowance of approximately $3,175,000 and $2,459,000 as of May 31, 2020 and 2019, respectively. The net change in the valuation allowance for the years ended May 31, 2020 and 2019 was an increase of $716,000 and $900,000, respectively. At May 31, 2020, the Company has Federal income tax NOL carryforwards of approximately $9,213,000. At May 31, 2020, the Company has California state income tax net operating loss carryforwards of approximately $5,025,000. At May 31, 2020, the Company has Federal research and development tax credit carryforward of approximately $438,000. The Federal credits begin to expire in 2027. The Company also had similar credit carryforwards for state purposes of $160,000 at May 31, 2020. Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company's net operating loss ("NOL") and credit carryforwards may be limited by statute because of a cumulative change in ownership of more than 50%. Pursuant to Sections 382 and 383 of the IRC, the annual use of the Company's NOLs and credit carryforwards would be limited if there is a cumulative change of ownership (as that term is defined in Section 382(g) of the IRC of greater than 50% in a three-year period. Management has not performed an analysis to determine if the Company has had a cumulative change in ownership of greater than 50%. For the year ended May 31, 2020, the Company did an analysis of its ASC 740 position and has not identified any uncertain tax positions as defined under ASC 740. Should such position be identified in the future and should the Company owe interest and penalties as a result of this, these would be recognized as interest expense and other expense, respectively, in the consolidated financial statements. The Company is no longer subject to any significant U.S. federal tax examinations by tax authorities for years before fiscal year 2016.

GEOGRAPHIC INFORMATION

GEOGRAPHIC INFORMATION	12 Months Ended
	May 31, 2020
Geographic Information Disclosure [Abstract]
Geographic Information Disclosure [Text Block]	7. GEOGRAPHIC INFORMATION The Company operates as one segment. Geographic information regarding net sales is approximately as follows: Years ended May 31, 2020 2019 Net sales: Europe $ 2,434,000 $ 1,694,000 United States 445,000 523,000 Asia 1,867,000 2,514,000 South America 1,615,000 256,000 Middle East 314,000 214,000 Other foreign 18,000 -- Total net sales $ 6,693,000 $ 5,201,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	May 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. COMMITMENTS AND CONTINGENCIES OPERATING LEASES On June 18, 2009, the Company entered into an agreement to lease a building in Irvine, California. The lease commenced September 1, 2009 and ended August 31, 2016. On November 30, 2015, the Company entered into the First Amendment to Lease wherein it exercised its option to extend its lease until August 31, 2021. The initial base rent for the lease extension was $21,000 per month, increasing to $23,637 through August 31, 2021. The monthly rent is currently $22,948. The security deposit of $22,080 remains the same. In November 2016, the Company’s subsidiary, Biomerica de Mexico, entered into a ten-year lease for approximately 8,104 square feet at a monthly rent of $2,926. The Company has one 10-year option to renew at the end of the initial lease period. The yearly rate is subject to an annual adjustment for inflation according to the United States Bureau of Labor Statistics Consumer Price Index for All Urban Consumers. The monthly rate is currently $3,239. Biomerica, Inc. is not a guarantor of such lease. Total gross rent expense in the U.S. for fiscal 2020 was $300,267 and 2019 was $268,550. Rent expense for the Mexico facility for fiscal 2020 and 2019 was $43,481 and $46,040, respectively. For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal options periods that the Company is reasonably certain of exercising. The Company’s office and equipment leases generally have contractually specified minimum rent and annual rent increases are included in the measurement of the right-of-use asset and related lease liability. Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for some maintenance and operating costs. Such amounts are generally variable and therefore not included in the measurement of the right-of-use asset and related lease liability but are instead recognized as variable lease expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss when they are incurred. Supplemental cash flow information related to leases for the year ended May 31, 2020: Operating cash flows from operating leases $ 311,742 Right-of-use assets obtained in exchange for -- Weighted average remaining lease term (in years) 6.27 Weighted average discount rate 6.5% The maturity of lease liabilities as of May 31, 2020 are as follows: Years ending May 31, 2021 $ 211,808 2022 236,391 2023 262,810 2024 291,329 2025 322,098 Thereafter 457,051 Total $ 1,781,487 According to the terms of the lease in Irvine, the Company is also responsible for routine repairs of the building and for certain increases in property tax. The Company also has various insignificant leases for office equipment. RETIREMENT SAVINGS PLAN Effective September 1, 1986, the Company established a 401(k) plan for the benefit of its employees. The plan permits eligible employees to contribute to the plan up to the maximum percentage of total annual compensation allowable under the limits of IRC Sections 415, 401(k) and 404. The Company, at the discretion of its Board of Directors, may make contributions to the plan in amounts determined by the Board each year. No contributions by the Company have been made since the plan's inception. LITIGATION The Company is, from time to time, involved in legal proceedings, claims and litigation arising in the ordinary course of business. While the amounts claimed may be substantial, the ultimate liability cannot presently be determined because of considerable uncertainties that exist. Therefore, it is possible the outcome of such legal proceedings, claims and litigation could have a material effect on quarterly or annual operating results or cash flows when resolved in a future period. However, based on facts currently available, management believes such matters will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. There were no legal proceedings pending as of May 31, 2020. On July 2, 2020, we received a notice of investigation and subpoena to produce information and documents from the Division of Enforcement of the SEC. The subpoena seeks information and documents related to events and circumstances leading up to our March 17, 2020 announcement that we had commenced shipping samples of our COVID-19 IgG/IgM Rapid Test to countries outside of the United States, and had initiated the application process with the United States Food and Drug Administration under the COVID-19 Emergency Use Authorization for approval to market and sell the test in the United States. The subpoena also seeks information and documents about the identity of any persons who were aware of the substance of the March 17, 2020 announcement prior to that date. We are cooperating and intends to continue cooperating fully with the SEC’s investigation. At this time, we are unable to predict the duration, scope or outcome of this investigation. CONTRACTS Contracts and Licensing Agreements The Company has one royalty agreement in which it has obtained rights to manufacture and market certain products for the life of the products. Royalty expense of approximately $15,000 and $19,000 is included in cost of sales for the agreement for each of the years ended May 31, 2020 and 2019, respectively. Sales of products manufactured under these agreements comprise approximately 1.8% and 2.9% of total sales for the years ended May 31, 2020 and 2019, respectively. The Company may license other products or technology in the future as it deems necessary for conducting business. The Company has other royalty agreements, however they are not considered material. On May 25, 2016, the Company entered into an Exclusive Marketing License Agreement (“ Telcon Agreement”) with Celtis Pharm Co., Ltd., who subsequently changed their name to Telcon Pharmaceutical Co., LTD (“Telcon”), a medical company in the South Korea. The Telcon Agreement grants to Telcon an exclusive license to market and sell Biomerica’s new InFoods® IBS products (“IBS Products”) in South Korea. The term of the agreement is for a period of five years following Korean FDA clearance of the product and provides an additional two years for Telcon to attain such Korean FDA clearance. The sequential two-year and five-year terms do not begin until after Biomerica first receives final clearance for sale of the IBS Products in the United States from the FDA. Telcon, at its sole cost and expense, must use its commercially reasonable good faith efforts to obtain Korean FDA for the IBS Product to be sold in South Korea. The agreement may be cancelled if Biomerica has not obtained final USFDA clearance for sale of the IBS Products on or before December 31, 2019. Biomerica is also obligated to maintain a full quality assurance system for the IBS Products following the harmonized standards according to Annex IV of Directive 98/79/EC. We are working with Telcon management to extend the term of the Telcon Agreement. The terms of the Telcon Agreement provide up to $1.25 million in exclusivity fees based on certain milestones including Biomerica’s starting clinical trials in the United States, receipt of US FDA clearance and Telcon’s first sales of IBS Products in Korea. If Biomerica commences FDA Trials and Telcon pays the initial $250,000 milestone-based exclusivity fees, and the Agreement is subsequently terminated by either party for lack of performance, then Biomerica shall issue to Telcon 83,333 shares of Biomerica common in consideration for the $250,000 of paid exclusivity fee. No exclusivity fees have yet been paid. Additionally, the Telcon Agreement provides for a royalty of 15% paid to Biomerica on all sales in Korea of the IBS Product, and further sets the pricing of IBS Products sold to Telcon. In order to retain the exclusivity within South Korean, Telcon must meet certain annual minimum royalty payments to Biomerica following Telcon’s receipt of Korean FDA approval or clearance for the IBS Product to be sold in Korea, which in no case will be later than May 31, 2019. In October 2018, the Company entered into an agreement with a customer for the sale of its EZ Detect product in the United States. The term of the Agreement is for three years and is renewable for one-year terms upon written notice. The agreement defines the price and rebate to the customer. There were no sales under this agreement in fiscal 2020. In December 2018, the Company entered into an agreement with a company for the purpose of procuring and assisting in transactions related to its EZ Detect product with China. The contract is for a period of twelve months and is cancellable by either party with forty-five days written notice. The contract specifies 2.5-6% success fees and milestone payments upon certain events transpiring. During fiscal 2019, the Company incurred $27,579 in expenses for this contract. There were no expenses incurred in fiscal 2020. In April 2019, the Company entered into a consulting agreement with the former, retired president of the Company. The agreement stipulates that he shall be available by consultation if needed for the period of April 8, 2019 through April 7, 2020. In return, the Company has agreed to allow his stock options in the Company to continue to vest and be exercisable until April 7, 2020. At that time, no options will vest and any vested, unexercised options must be exercised by July 2, 2020 at which time they will be forfeited. All options that were eligible to vest according to this agreement were vested and exercised. There were no fees incurred for this agreement for consultation services. In May 2019, the Company entered into an agreement with MaxHealth Medical International Limited and MaxHealth China (“MaxHealth”) giving MaxHealth exclusive distribution rights to Biomerica’s EZ Detect Product in China. Among other things, the Agreement called for MaxHealth to deposit $100,000 upon execution of the agreement, and an additional $900,000 (for a total of $1,000,000 USD) upon clearance of Chinese customs of the initial order of $100,000. The $1,000,000 was to be used as a prepayment for the first $1,000,000 of purchase orders for the product. While the Company received the first deposit of $100,000, and shipped $100,000 of product to Maxhealth, the Company has not received the second deposit, and has not shipped any further product, which has placed MaxHealth in Default of the agreement. MaxHealth and the Company have been negotiating a possible remedy for the default. There is no assurance these negotiations will be successful or that the default will be rectified. On April 1, 2020, the Company entered into two separate non-exclusive license agreements (the “Mount Sinai License Agreements”) with the Mount Sinai Icahn School of Medicine in New York (“Mount Sinai”) to license technology from Mount Sinai that the Company intends to use to scale up and manufacture a laboratory version serological test for SARS-CoV-2 coronavirus. This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States. The non-exclusive Mount Sinai License Agreements provide for royalty payments to Mount Sinai based on a percentage of gross sales of commercial products manufactured and sold by Biomerica that incorporate the Mount Sinai technology licensed under the Mount Sinai License Agreement. On June 20, 2020, the Company filed for EUA with the FDA based on this on this technology. The Company purchased materials in the amount of $5,100 during fiscal 2020 and subsequently to that another $2,850. No royalty fees have been paid yet on these agreements. On May 7, 2020, the Company entered into an exclusive license agreement (the “UC License Agreements”) with The Regents of the University of California (“UC”) to license all patent rights pertaining to certain licensed technology from UC. This technology is being developed at the University by one of the professors and his team utilizing CRISPR technology. This group is developing a viral detection test for SARS-CoV-2 coronavirus. If this technology development is successful, the Company will work with the University to transfer the technology to Biomerica where the CRISPR based product will need to be further developed, validated and cleared with regulatory agencies for commercial sale into the market. The exclusive UC License Agreements provide for an initial and annual license fee, and a royalty payment on all commercial revenues, to the UC Regents. The UC License Agreement also includes certain investment requirements and milestones the Company will need to meet for the launch of a commercial product based on the licensed technology. The Company paid an initial license fee of $5,000 with the execution of the agreement. An additional $5,000 is due in September 2020. No royalties have been paid yet on this agreement. A license maintenance fee of $10,000 is due annually. This is creditable against earned royalties due each year in the amount of five percent on net sales of licensed products. On May 18, 2020, the Company signed a non-exclusive distributor agreement with a company in Russia for the distribution of COVID-19 tests. The term of the agreement is for an initial two years, however, the agreement may be terminated for breach of contract. The agreement allows for quantity discounts based on certain milestones. Clinical Trial Agreements In September 2017, the Company signed a Clinical Samples Agreement with the University of Southern California for the purpose of providing clinical samples for use by the Company in conducting future clinical trials for one of the products which the Company is developing. The initial budget was estimated to be $82,472. The work started in October 2017 with charges for work performed being invoiced and paid monthly. This study ended in February 2020. The Company incurred $2,200 in fiscal 2020 and $12,567 in expenses previously invoiced for a total of $14,767. In addition, $17,064 in fees has been accrued for unbilled charges as of May 31, 2020. In November 2017, the Company entered into a Clinical Trial Agreement with the University of Michigan to perform an InFoods 24 Endpoint Determination Study. The Company will be invoiced monthly for work performed the previous month. The maximum budget for the study is $181,015. The Company incurred $30,900 and $40,885 in expenses for this study during fiscal 2020 and 2019, respectively. This commitment is approximately 47% billed. In January 2018, the Company entered into a Clinical Trial Agreement with Beth Israel Deaconess Medical Center for the purposes of conducting an Antibody Guided Restriction Trial Using Biomerica InFoods 24G Test in patients with a previous diagnosis of Irritable Bowel Syndrome (“IBS”). The study began in the first quarter of fiscal 2019. The Company was invoiced monthly for work performed the previous month. The total cost of the study was initially estimated to be $142,000, however the study was expanded and total costs of the trial was approximately $305,000. The Company incurred $141,640 and $146,760 in expenses for this study during fiscal 2020 and 2019, respectively. This study was closed in February 2020 and no additional costs are expected. On July 12, 2019, the Company entered into a Clinical Trial Agreement with a research management institution for the purpose of conducting a clinical trial of the Biomerica HP Stool Antigen test. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs was approximately $117,200. During fiscal 2020, $13,111 in charges were billed and the Company accrued $6,670 in charges as of May 31, 2020. This study is now closed so no further charges will be incurred. On July 22, 2019, the Company entered into a Clinical Trial Agreement with a research institution, for the purpose of conducting a clinical trial of the Biomerica Infoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $107,000. The Company incurred $20,875 in charges during fiscal 2020. This commitment is approximately 19% billed. In addition, the Company accrued $2,650 in unbilled charges as of May 31, 2020. On September 25, 2019, the Company entered into a Clinical Trial Agreement with a medical practice for the purpose of conducting a clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $136,000. During fiscal 2020, the Company was invoiced $45,250 in expenses. This commitment is approximately 33% billed. In addition, the Company accrued $5,975 in unbilled charges as of May 31, 2020. On September 25, 2019, the Company entered into a Clinical Trial Agreement with a research institution for the purpose of conducting a clinical trial of the Biomerica H. pylori product. The term of the agreement shall be until completion of the work outlined and the charges were invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $57,800. The Company was invoiced $41,845 in charges during the year ended May 31, 2020. At May 31, 2020, the commitment was approximately 72% billed and the study has been closed so no further charges will be incurred. In December 2019, the Company entered into a Clinical Trial Agreement with Houston Methodist Research Institute for the purpose of conducting a clinical trial of the Biomerica InFoods® IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be approximately $133,000. During the year ended May 31, 2020, the Company was invoiced $4,000 in charges. This commitment is approximately 3% billed. On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Arizona for the purpose of participating in the ongoing end point clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. At May 31, 2020, $17,390 had been invoiced to the Company. This commitment is approximately 13% billed. On May 28, 2020, the Company entered into a Clinical Trial Agreement with the Mayo Clinic Jacksonville for the purpose of participating in the ongoing end point clinical trial of the Biomerica Infoods IBS product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $135,515. The Company has not received any billings as of May 31, 2020, however accrued $17,390 in charges as of that date. The addition of both Mayo Clinic sites and other major medical centers were brought into the Infoods® IBS clinicals studies in order to accelerate patient enrollment.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	May 31, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	9. SUBSEQUENT EVENTS Subsequent to May 31, 2020 and through August 31, 2020, 12,500 stock options were exercised at $1.20 per share. Net proceeds to the Company were approximately $14,900. On June 15, 2020, the Board approved the grant of 52,000 stock options to certain employees. The options vest one-quarter on June 15, 2021 and then one-quarter per year thereafter. The options have an exercise price of $5.46 per share and have a ten-year life. On July 13, 2020, the Board approved the grant of 76,000 stock options to certain employees and consultants. The options vest one-quarter on July 13, 2021 and then one-quarter per year thereafter. The options have an exercise price of $8.70 per share and have a ten-year life. On July 13, 2020, the approved the grant of 7,500 stock options to a consultant. The options vest one-half on January 13, 2021 and one-half on July 13, 2021. The options have an exercise price of $8.70 per share and have a ten-year life. On June 25, 2020, the Company entered into a Clinical Trial Agreement with the University of Texas Health Science Center for the purpose of conducting a clinical trial of the Biomerica Infoods product. The term of the agreement shall be until completion of the work outlined and the charges will be invoiced monthly for work performed in the previous month. The maximum budgeted costs will be $139,850. On July 20, 2020, the Company filed with the SEC a new Form S-3 “Shelf” registration statement to replace the registration statement that expired on that day. The new registration statement registers common shares to be issued in a maximum aggregate of $90,000,000. On August 27, 2020, the Board approved the grant of 33,000 stock options to an employee and a board member. The options vest one-quarter on August 27, 2021 and then one-quarter per year thereafter. The options have an exercise price of $7.47 per share and have a ten-year life. On August 27, 2020, the Board approved the grant of 2,500 stock options to a consultant. The options vest one-half on January 13, 2021 and 50% on July 13, 2021. The options have an exercise price of $7.47 per share and have a ten-year life.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	May 31, 2020
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	PRINCIPLES OF CONSOLIDATION The enclosed consolidated financial statements for the years ended May 31, 2020 and 2019 include the accounts of Biomerica, Inc. ("Biomerica") as well as its German subsidiary (BioEurope GmbH) and Mexican subsidiary (Biomerica de Mexico). All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	ACCOUNTING ESTIMATES The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical past practices with a customer; stock option forfeiture rates, which are calculated based on historical data; and inventory obsolescence, which are based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, likelihood of lease extensions to occur, asset valuation, among other things; (and other items that may be necessary to estimate using current, historical and judgment based). Actual results could materially differ from those estimates.
Fair Value Measurement, Policy [Policy Text Block]	FAIR VALUE OF FINANCIAL INSTRUMENTS The Company has financial instruments whereby the fair market value of the financial instruments could be different than that recorded on a historical basis. The Company's financial instruments consist of its cash and cash equivalents, accounts receivable, and accounts payable. The carrying amounts of the Company's financial instruments approximate their fair values.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	CONCENTRATION OF CREDIT RISK The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. As of May 31, 2020, the Company had approximately $8,595,241 of uninsured cash. The Company does not believe it is exposed to any significant credit risks. The Company provides credit in the normal course of business to customers throughout the United States and in foreign markets. The Company performs ongoing credit evaluations of its customers and requires accelerated prepayment in some circumstances. For the years ended May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 57.2% and 46.3% of our net consolidated sales, respectively. Of this, for the years ended May 31, 2020 and 2019 one of the distributors mentioned above accounted for 25.7% and 36.3%, respectively, of net consolidated sales. At May 31, 2020 and 2019, the Company had three distributors and two distributors which accounted for a total of 80.0% and 68.1%, respectively, of gross accounts receivable. Of the 80.0% as of May 31, 2020, 43.9% was owed by a distributor in Ecuador. Total gross receivables at May 31, 2020 and 2019 were $1,836,852 and $1,527,762, respectively. For the year ended May 31, 2020, one vendor accounted for 59.3% of the purchases of raw materials. For the year ended May 31, 2019, two vendors accounted for a total of 23.8 % of the purchases of raw materials.
Concentration Risk Geographic Policy [Policy Text Block]	GEOGRAPHIC CONCENTRATION As of May 31, 2020 and 2019, approximately $613,000 and $665,000 of Biomerica's gross inventory and approximately $31,000 and $39,000, of Biomerica's property and equipment, net of accumulated depreciation, was located in Mexicali, Mexico, respectively.
Cash and Cash Equivalents, Policy [Policy Text Block]	CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of demand deposits and money market accounts with original maturities of less than three months.
Accounts Receivable [Policy Text Block]	ACCOUNTS RECEIVABLE The Company extends unsecured credit to its customers on a regular basis. International accounts are required to prepay until they establish a history with the Company and at that time, they are extended credit at levels based on a number of criteria. Based on various criteria, initial credit levels for individual distributors are approved by designated officers and managers of the company. All increases in credit limits are also approved by designated upper level management. Management evaluates receivables on a quarterly basis and adjusts the allowance for doubtful accounts accordingly. Balances over ninety days old are usually reserved for unless collection is reasonably assured. Occasionally certain long-standing customers, who routinely place large orders, will have unusually large receivables balances relative to the total gross receivables. Management monitors the payments for these large balances closely and very often requires payment of existing invoices before shipping new sales orders.
Inventory, Policy [Policy Text Block]	INVENTORIES The Company values inventory at the lower of cost (determined using a combination of specific lot identification and the first-in, first-out methods) or net realizable value. Management periodically reviews inventory for excess quantities and obsolescence. Management evaluates quantities on hand, physical condition, and technical functionality as these characteristics may be impacted by anticipated customer demand for current products and new product introductions. The reserve is adjusted based on such evaluation, with a corresponding provision included in cost of sales. Abnormal amounts of idle facility expenses, freight, handling costs and wasted material are recognized as current period charges and the allocation of fixed production overhead is based on the normal capacity of the production facilities. Inventories approximate the following at May 31: 2020 2019 Raw materials $ 1,635,000 $ 1,208,000 Work in progress 988,000 771,000 Finished products 228,000 172,000 Total $ 2,851,000 $ 2,151,000 Reserves for inventory obsolescence are recorded as necessary to reduce obsolete inventory to estimated net realizable value or to specifically reserve for obsolete inventory that the Company intends to dispose of. As of May 31, 2020 and 2019, inventory reserves were approximately $67,000 and $49,000, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	PROPERTY AND EQUIPMENT Property and equipment are stated at cost. Expenditures for additions and major improvements are capitalized. Repairs and maintenance costs are charged to operations as incurred. When property and equipment are sold, retired or otherwise disposed of, the related cost and accumulated depreciation or amortization are removed from the accounts, and gains or losses from sales, retirements and dispositions are credited or charged to income. Depreciation and amortization are provided over the estimated useful lives of the related assets, ranging from 5 to 10 years, using the straight-line method. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Depreciation and amortization expense on property and equipment amounted to $105,299 and $101,216 for the years ended May 31, 2020 and 2019, respectively.
Goodwill and Intangible Assets, Policy [Policy Text Block]	INTANGIBLE ASSETS Intangible assets include trademarks, product rights, technology rights and patents, and are accounted for based on Accounting Standards Codification (“ASC”), ASC 350 Intangibles – Goodwill and Other (“ASC 350”). In that regard, intangible assets that have indefinite useful lives are not amortized but are tested at least annually for impairment or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets are being amortized using the straight-line method over the useful life, not to exceed 18 years for marketing and distribution rights, 10 years for purchased technology use rights, and 20 years for patents. Amortization amounted to $23,873 and $61,689 for the years ended May 31, 2020 and 2019, respectively. The Company assesses the recoverability of these intangible assets by determining whether the amortization of the asset's balance over its remaining life can be recovered through projected undiscounted future cash flows. The Company uses a qualitative assessment to determine whether there was any impairment. No impairment adjustment was required as of May 31, 2020 or 2019.
Investment, Policy [Policy Text Block]	INVESTMENTS From time-to-time, the Company makes investments in privately-held companies. The Company determines whether the fair values of any investments in privately-held entities have declined below their carrying value whenever adverse events or changes in circumstances indicate that recorded values may not be recoverable. If the Company considers any such decline to be other than temporary (based on various factors, including historical financial results, and the overall health of the investee’s industry), a write-down to estimated fair value is recorded. Investments represent the Company’s investment in a Polish distributor which is primarily engaged in distributing medical products and devices. The Company currently has not written down the investment and no events have occurred which could indicate the carrying value of the investment to be greater than the fair value. The Company owns approximately 6% of the investee and, accordingly, applies the cost method to account for the investment. Under the cost method, investments are recorded at cost, with gains and losses recognized as of the sale date, and income recorded when received.
Share-based Payment Arrangement [Policy Text Block]	SHARE-BASED COMPENSATION The Company follows the guidance of the accounting provisions of ASC 718 , The Company has not paid dividends historically and does not expect to pay them in the foreseeable future. In applying the Black-Scholes options-pricing model, assumptions used were as follows: 2020 2019 Dividend yield 0% 0% Expected volatility 55.52-72.62% 57.90-60.41% Risk free interest rate 0.43-1.80% 2.33-2.85% Expected life 3.75-6.25 years 3.75-6.25 years
Revenue [Policy Text Block]	REVENUE RECOGNITION The Company has various contracts with customers. All of the contracts specify that revenues from product sales are recognized at the time the product is shipped, customarily FOB shipping point, which is when the transfer of control of goods has occurred and at which point title passes. The Company does not allow for returns except in the event of defective merchandise and therefore does not establish an allowance for returns. In addition, the Company has contracts with customers wherein they receive purchase discounts for achieving specified sales volumes. The Company evaluated the status of these contracts as of May 31, 2020 and does not believe that any additional discounts will be given through the end of the contract periods. Services for some contract work are invoiced and recognized for work that has been performed as the project progresses. The Company sells clinical lab products to domestic and international distributors, including hospitals and clinical laboratories, medical research institutions, medical schools and pharmaceutical companies. OTC products are sold directly to drug stores and e-commerce customers as well as to distributors. Physicians’ office products are sold to physicians and distributors, all of whom are categorized below according to the type of products sold to them. We also manufacture certain components on a contract basis for domestic and international manufacturers. Disaggregation of revenue: The following is a breakdown of revenues according to markets to which the products are sold: Year Ended May 31, 2020 May 31, 2019 Clinical Lab $ 2,922,425 $ 4,043,993 OTC 1,269,535 868,605 Physicians’ Office 2,194,991 170,871 Contract Manufacturing 305,760 117,213 Total $ 6,692,711 $ 5,200,682 See Note 7 for additional information regarding revenue concentrations.
Cost of Goods and Service [Policy Text Block]	SHIPPING AND HANDLING FEES The Company includes shipping and handling fees billed to customers in net sales.
Research and Development Expense, Policy [Policy Text Block]	RESEARCH AND DEVELOPMENT Research and development costs are expensed as incurred. The Company expensed $1,910,209 and $1,679,098 of research and development costs during the years ended May 31, 2020 and 2019, respectively.
Income Tax, Policy [Policy Text Block]	INCOME TAXES The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities arise from temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years and the benefits of net operating loss and tax credit carryforwards. These temporary differences and the benefits of net operating loss and tax credit carryforwards are measured using enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets to the extent that management considers it is more likely than not that a deferred tax asset will not be realized. In determining the valuation allowance, the Company considers factors such as the reversal of deferred income tax assets, projected taxable income, and the character of income tax assets and tax planning strategies. A change to these factors could impact the estimated valuation allowance and income tax expense. At May 31, 2020 and 2019, in accordance with ASC 740, the Company has a valuation allowance for substantially all of its deferred tax assets. During the fiscal year ended May 31, 2020, this valuation allowance was increased to approximately $ 3,175,000, which fully covers the net tax asset of $3,175,000 . The Company accounts for its uncertain tax provisions by using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not, based solely on the technical merits, that the position will be sustained in an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the appropriate amount of the benefit to recognize. The amount of benefit to recognize is measured as the maximum amount which is more likely than not to be realized. The tax position is derecognized when it is no longer more likely than not capable of being sustained. On subsequent recognition and measurement the maximum amount which is more likely than not to be recognized at each reporting date will represent the Company’s best estimate, given the information available at the reporting date, although the outcome of the tax position is not absolute or final. Upon adopting the revisions in ASC 740, the Company elected to follow an accounting policy to classify accrued interest related to liabilities for income taxes within the “Interest expense” line and penalties related to liabilities for income taxes within the “Other expense” line of the consolidated statements of operations and comprehensive loss.
Advertising Cost [Policy Text Block]	ADVERTISING COSTS The Company reports the cost of all advertising as expense in the period in which those costs are incurred. Advertising costs were approximately $174
Foreign Currency Transactions and Translations Policy [Policy Text Block]	FOREIGN CURRENCY TRANSLATION The subsidiary located in Mexico operates primarily using the Mexican peso. The subsidiary located in Germany operates primarily using the U.S. dollar, with an immaterial amount of transactions occurring using the Euro. Accordingly, assets and liabilities of these subsidiaries are translated using exchange rates in effect at the end of the year, and revenues and costs are translated using average exchange rates for the year. The resulting adjustments to assets and liabilities are presented as a separate component of accumulated other comprehensive loss. There are no adjustments to foreign currency loss that are included in the consolidated statements of operations for the years ended May 31, 2020 and 2019.
Lessee, Leases [Policy Text Block]	RIGHT-OF-USE ASSETS AND LEASE LIABILITY Incentive payments received from landlords are recorded as deferred lease incentives and are amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. When the terms of an operating lease provide for periods of free rent, rent concessions, and/or rent escalations, the Company establishes a deferred rent liability for the difference between the scheduled rent payment and the straight-line rent expense recognized. This deferred rent liability was amortized over the underlying lease term on a straight-line basis as a reduction of rent expense. During the year ended May 31, 2020, the Company adopted ASC 842, Leases. As a result, the existing deferred rent liability was netted against the Right-of-Use Asset which was capitalized at that time. In February 2016, the Financial Accounting Standards Board (“FASB”) issued an accounting standards update which requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Right-of-Use assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. Leases will be classified as financing or operating which will drive the expense recognition pattern. For lessees, the statement of operations presentation and expense recognition pattern for financing and operating leases is similar to the current model for capital and operating leases, respectively. The Company has elected to exclude short-term leases. The update also requires additional disclosures that will better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted this guidance as of June 1, 2019, the required effective date, using the effective date transition method. As permitted under the effective date transition method, financial information and disclosure for periods prior to the date of initial application will not be updated. An adjustment to opening accumulated deficit was not required in conjunction with adoption. The adoption of this statement resulted in a right-of-use asset being recorded in the amount of $1,942,999 and a lease liability being recorded in the amount of $1,980,970. Both will be amortized over the life of the underlying leases. For additional information, see Note 8-Commitments and Contingencies. The Company has elected not to reassess whether expired or existing contracts contain leases, or reassess the classification of existing leases as of the adoption date. The Company leases office space and copy machines, all of which are operating leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The leases do not include the options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term.
Earnings Per Share, Policy [Policy Text Block]	NET LOSS PER SHARE Basic loss per share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur from common shares issuable through stock options, warrants and other convertible securities using the treasury stock method. The total amounts of anti-dilutive stock options not included in the loss per share calculation for the years ended May 31, 2020 and 2019 were 1,789,251 and 1,476,209, respectively. The Company also has outstanding 321,429 of Series A 5% Convertible Preferred Stock, which may be converted at any time to common stock.
Segment Reporting, Policy [Policy Text Block]	SEGMENT REPORTING ASC 280, Segment Reporting (“ASC 280”), establishes standards for reporting, by public business enterprises, information about operating segments, products and services, geographic areas, and major customers. The Company’s operations are analyzed by management and its chief operating decision maker as being part of a single industry segment: the design, development, marketing and sales of diagnostic kits.
Comprehensive Income, Policy [Policy Text Block]	REPORTING COMPREHENSIVE LOSS Comprehensive loss represents net loss and any revenues, expenses, gains and losses that, under GAAP, are excluded from net loss and recognized directly as a component of shareholders’ equity. Accumulated other comprehensive loss consists solely of foreign currency translation adjustments.
New Accounting Pronouncements, Policy [Policy Text Block]	RECENT ACCOUNTING PRONOUNCEMENTS On February 15, 2018, the FASB issued ASU 2018-02, “Reclassification of Certain Tax Effects From Accumulated Comprehensive Income” (“ASU 2018-02”). ASU 2018-02 will give companies the option to reclassify stranded tax effects caused by the newly-enacted U.S. Tax Cuts and Jobs Act (“TCJA”) from accumulated other comprehensive income (“ASCI”) to retained earnings. ASU 2018-02 was effective for all companies for the fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Management is taking the provisions of this statement into account in the preparation of the consolidated financial statements for the year ended May 31, 2020. The adoption of this standard has not had a significant impact on the Company’s consolidated financial statements. On June 20, 2018, the FASB issued ASU 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for share-based payments to nonemployees (service providers, external legal counsel, and suppliers). ASU 2018-07 was effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. During the year ended May 31, 2020, the Company adopted the provisions of this statement and is taking them into account in the preparation of the consolidated financial statements for the year ended May 31, 2020. The adoption of this standard has not had a significant impact on the Company’s consolidated financial statements. Other recent ASU's issued by the FASB and guidance issued by the Securities and Exchange Commission (“SEC”) did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	May 31, 2020
Accounting Policies [Abstract]
Schedule of Inventory, Current [Table Text Block]	2020 2019 Raw materials $ 1,635,000 $ 1,208,000 Work in progress 988,000 771,000 Finished products 228,000 172,000 Total $ 2,851,000 $ 2,151,000
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2020 2019 Dividend yield 0% 0% Expected volatility 55.52-72.62% 57.90-60.41% Risk free interest rate 0.43-1.80% 2.33-2.85% Expected life 3.75-6.25 years 3.75-6.25 years
Disaggregation of Revenue [Table Text Block]	Year Ended May 31, 2020 May 31, 2019 Clinical Lab $ 2,922,425 $ 4,043,993 OTC 1,269,535 868,605 Physicians’ Office 2,194,991 170,871 Contract Manufacturing 305,760 117,213 Total $ 6,692,711 $ 5,200,682

INTANGIBLE ASSETS, NET (Tables)

INTANGIBLE ASSETS, NET (Tables)	12 Months Ended
	May 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2020 2019 Licenses $ 551,397 $ 510,600 Patents 113,382 68,860 Less accumulated amortization- (487,989) (471,530) Less accumulated amortization- (8,135) (721) Intangible assets, net $ 168,655 $ 107,209
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2021 $ 18,112 2022 8,503 2023 6,211 2024 6,136 2025 5,219 Thereafter 124,474 Total $ 168,655

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	May 31, 2020
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	2020 2019 Accounts payable and accrued expenses $ 986,711 $ 999,594 Deferred rent - 37,971 $ 986,711 $ 1,037,565

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	May 31, 2020
Stockholders' Equity Note [Abstract]
Share-based Payment Arrangement, Option, Activity [Table Text Block]	NUMBER OF STOCK OPTIONS EXERCISE PRICE RANGE PER SHARE WEIGHTED AVERAGE EXERCISE PRICE Options outstanding at May 31, 2018 1,138,625 $0.71-$3.90 $ 1.65 Options granted 558,000 $2.25-$3.62 $ 2.60 Options exercised (163,500) $0.71-$1.04 $ 0.76 Options canceled or expired (56,916) $0.71-$3.62 $ 2.49 Options outstanding at May 31, 2019 1,476,209 $0.82-$3.90 $ 2.07 Options granted 517,500 $2.68-$8.18 $ 4.47 Options exercised (137,958) $0.82-$3.90 $ 1.64 Options canceled or expired (66,500) $0.85-$8.18 $ 3.43 Options outstanding at May 31, 2020 1,789,251 $0.82-$8.18 $ 2.75
Schedule of Nonvested Share Activity [Table Text Block]	NUMBER OF SHARES STOCK OPTIONS WEIGHTED AVERAGE AVERAGE GRANT DATE FAIR VALUE Non-vested shares at May 31, 2019 769,584 $ 2.49 Granted 517,500 $ 4.47 Vested (407,750) $ 2.25 Forfeited (56,750) $ 3.55 Non-vested shares at May 31, 2020 822,584 $ 3.78
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	RANGE OF EXERCISE PRICES NUMBER OUTSTANDING May 31, 2020 WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE IN YEARS WEIGHTED AVERAGE EXERCISE PRICE NUMBER EXERCISABLE AT MAY 31, 2020 WEIGHTED AVERAGE EXERCISE PRICE $ 0.82-$1.04 276,000 4.44 $0.84 276,000 $0.84 $ 1.20-$ 2.81 1,072,500 7.57 $2.17 506,000 $1.71 $ 3.62-$ 8.18 440,751 7.62 $5.38 184,667 $3.87

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	May 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Years ended May 31, 2020 2019 Current: U.S. Federal $ -- $ -- Foreign Taxes Subsidiaries (6,590) (13,437) State and local (800) (800) Total current (7,390) (14,237) Deferred: U.S. Federal -- (10,000) State and local -- -- Total deferred -- (10,000) Income tax expense $ (7,390) $ (24,237)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Years ended May 31, 2020 2019 Computed "expected" tax benefit $ 489,651 $ 497,453 Increase (reduction) in income taxes resulting from: Change in valuation allowance (716,000) (910,000) State income taxes, net of federal benefit 154,254 89,267 Research and development tax credits 49,770 55,908 Permanent tax differences and other 21,525 (256,572) Foreign taxes of subsidiaries (6,590) (13,437) Income tax expense $ (7,390) $ (24,237)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of May 31, 2020 2019 Deferred tax assets: Accounts receivable, principally due to allowance for doubtful accounts $ 17,000 $ 18,000 Inventory valuation 16,000 12,000 Compensated absences 64,000 48,000 Net operating loss carryforwards 2,286,000 1,735,000 Tax credit carryforwards 599,000 467,000 Deferred rent expense/Capitalized leases 17,000 9,000 Other 171,000 176,000 Accumulated depreciation and amortization 5,000 (6,000) Total deferred tax assets 3,175,000 2,459,000 Less valuation allowance (3,175,000) (2,459,000) Net deferred tax asset $ -- $ --

GEOGRAPHIC INFORMATION (Tables)

GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	May 31, 2020
Geographic Information Disclosure [Abstract]
Revenue from External Customers by Geographic Areas [Table Text Block]	Years ended May 31, 2020 2019 Net sales: Europe $ 2,434,000 $ 1,694,000 United States 445,000 523,000 Asia 1,867,000 2,514,000 South America 1,615,000 256,000 Middle East 314,000 214,000 Other foreign 18,000 -- Total net sales $ 6,693,000 $ 5,201,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	May 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule Of Cash Flow Supplemental Disclosures Related To Lease [Table Text Block]	Operating cash flows from operating leases $ 311,742 Right-of-use assets obtained in exchange for -- Weighted average remaining lease term (in years) 6.27 Weighted average discount rate 6.5%
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Years ending May 31, 2021 $ 211,808 2022 236,391 2023 262,810 2024 291,329 2025 322,098 Thereafter 457,051 Total $ 1,781,487

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	May 31, 2020	May 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Cash, Uninsured Amount	$ 8,595,241
Other Receivables, Gross, Current	1,836,852	$ 1,527,762
Property, Plant and Equipment, Net	$ 279,379	351,070
Threshold Period Past Due for Write-off of Trade Accounts Receivable	90 days
Inventory Valuation Reserves	$ 67,000	49,000
Depreciation, Depletion and Amortization	105,299	101,216
Amortization of Intangible Assets	$ 23,873	61,689
Equity Method Investment, Ownership Percentage	6.00%
Research and Development Expense	$ 1,910,209	1,679,098
Deferred Tax Assets, Valuation Allowance	3,175,000	2,459,000
Deferred Tax Assets, Gross	3,175,000	2,459,000
Advertising Expense	174	0
Operating Lease, Right-of-Use Asset	$ 1,711,510
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)	1,789,251	1,476,209
Minimum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Distribution Rights [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	18 years
Purchased Technology Rights [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Patents [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
MEXICO
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Inventory, Gross	$ 613,000	$ 665,000
Property, Plant and Equipment, Net	31,000	$ 39,000
Accounting Standards Update 2016-02 [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Operating Lease, Right-of-Use Asset	1,942,999
Operating Lease, Liability	$ 1,980,970
Three Distributors [Member] | Revenue Benchmark [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	57.20%
Three Distributors [Member] | Accounts Receivable [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	80.00%
Two Distributors [Member] | Revenue Benchmark [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		46.30%
Two Distributors [Member] | Accounts Receivable [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage		68.10%
One Distributors [Member] | Revenue Benchmark [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	25.70%	36.30%
Distributors in Ecuador [Member] | Accounts Receivable [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	43.90%
Supplier Concentration Risk [Member] | Cost of Goods and Service, Product and Service Benchmark [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	59.30%	23.80%
5% Convertible Preferred Stock [Member] | Common Stock [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)	321,429

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Inventories - USD ($)	May 31, 2020	May 31, 2019
Inventories [Abstract]
Raw materials	$ 1,635,000	$ 1,208,000
Work in progress	988,000	771,000
Finished products	228,000	172,000
Total	$ 2,850,836	$ 2,151,090

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions	12 Months Ended
	May 31, 2020	May 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]
Dividend yield	0.00%	0.00%
Minimum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]
Expected volatility	55.52%	57.90%
Risk free interest rate	0.43%	2.33%
Expected life	3 years 9 months	3 years 9 months
Maximum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Share based compensation assumptions [Line Items]
Expected volatility	72.62%	60.41%
Risk free interest rate	1.80%	2.85%
Expected life	6 years 3 months	6 years 3 months

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Revenue from contracts with customers - USD ($)	12 Months Ended
	May 31, 2020	May 31, 2019
Disaggregation of Revenue [Line Items]
Revenue From Customers	$ 6,692,711	$ 5,200,682
Clinical Lab [Member]
Disaggregation of Revenue [Line Items]
Revenue From Customers	2,922,425	4,043,993
OTC [Member]
Disaggregation of Revenue [Line Items]
Revenue From Customers	1,269,535	868,605
Physicians Office [Member]
Disaggregation of Revenue [Line Items]
Revenue From Customers	2,194,991	170,871
Contract Manufacturing [Member]
Disaggregation of Revenue [Line Items]
Revenue From Customers	$ 305,760	$ 117,213

INTANGIBLE ASSETS, NET (Details

INTANGIBLE ASSETS, NET (Details) - Intangible assets, net - USD ($)	May 31, 2020	May 31, 2019
Intangible assets, net [Abstract]
Licenses	$ 551,397	$ 510,600
Patents	113,382	68,860
Less accumulated amortization- licenses	(487,989)	(471,530)
Less accumulated amortization- patents	(8,135)	(721)
Intangible assets, net	$ 168,655	$ 107,209

INTANGIBLE ASSETS, NET (Detai_2

INTANGIBLE ASSETS, NET (Details) - Expected amortization of intangible assets	May 31, 2020USD ($)
Expected amortization of intangible assets [Abstract]
2021	$ 18,112
2022	8,503
2023	6,211
2024	6,136
2025	5,219
Thereafter	124,474
Total	$ 168,655

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts Payable [Member]	12 Months Ended
	May 31, 2020	May 31, 2019
Two Vendors [Member]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]
Concentration Risk, Percentage	26.90%
One Vendor [Member]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) [Line Items]
Concentration Risk, Percentage		32.10%

ACCOUNTS PAYABLE AND ACCRUED _4

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Accounts payable and accrued expense balances - USD ($)	May 31, 2020	May 31, 2019
Accounts payable and accrued expense balances [Abstract]
Accounts payable and accrued expenses	$ 986,711	$ 999,594
Deferred rent		37,971
Total	$ 986,711	$ 1,037,565

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details) - USD ($)

Mar. 24, 2020

Feb. 24, 2020

Dec. 31, 2017

Dec. 01, 2017

Jul. 20, 2017

Dec. 31, 2014

Aug. 31, 2010

May 31, 2020

May 31, 2019

Mar. 19, 2020

Feb. 29, 2020

Feb. 26, 2020

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

$ 4.47

Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in Dollars per share)

$ 0.71

Proceeds from Stock Options Exercised

$ 223,534

$ 121,790

Proceeds from Issuance of Common Stock

$ 10,232,857

$ 1,776,575

Common Stock [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)

137,958

163,500

Conversion of Stock, Shares Converted (in Shares)

250,000

Share-based Payment Arrangement, Option [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Payment Arrangement, Expense

$ 200,470

$ 151,224

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

$ 4.47

$ 2.60

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

$ 589,000

$ 364,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value

6,923,000

808,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value

4,442,000

685,000

Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount

$ 663,000

Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition

3 years 244 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

6 years 69 days

Share-based Payment Arrangement, Option [Member] | MEXICO

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Payment Arrangement, Expense

$ 0

48

Share-based Payment Arrangement, Option [Member] | 2010 Plan [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

850,000

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

80.00%

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Payment Arrangement, Option [Member] | 2014 Plan [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

850,000

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

80.00%

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Payment Arrangement, Option [Member] | 2017 Plan [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

900,000

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

80.00%

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Share-based Payment Arrangement, Option [Member] | 2020 Plan [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

900,000

Share-based Payment Arrangement, Option [Member] | Research and Development Expense [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Payment Arrangement, Expense

17,892

3,714

Share-based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Payment Arrangement, Expense

156,750

143,299

Share-based Payment Arrangement, Option [Member] | Selling and Marketing Expense [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Payment Arrangement, Expense

2,933

$ 4,163

Share-based Payment Arrangement, Option [Member] | Cost of Sales [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Payment Arrangement, Expense

$ 22,895

5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Preferred Stock, Shares Authorized (in Shares)

571,429

571,429

571,429

Conversion of Stock, Shares Converted (in Shares)

250,000

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

$ 0.08

$ 0.08

Preferred Stock, Dividends Per Share, Declared (in Dollars per share)

$ 0.175

Dividends, Preferred Stock

$ 18,000

5% Convertible Preferred Stock [Member] | Series A Preferred Stock [Member] | Common Stock [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Shares Issued, Price Per Share (in Dollars per share)

$ 3.50

Conversion of Stock, Amount Issued

$ 2,000,000

Conversion of Stock, Description

The Company may require the conversion of all of the outstanding Series A 5% Convertible Preferred Stock shares if the closing sale price of the Company’s common stock equals or exceeds $9.00 for a period of five consecutive trading days with a minimum average trading volume of 35,000 shares per day over such period; provided, that, on such date, the Conversion Shares are registered for resale

Conversion of Stock, Shares Issued (in Shares)

250,000

Payments of Stock Issuance Costs

$ 82,000

Common Stock [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Sale of Stock, Consideration Received on Transaction

10,232,857

$ 1,776,575

Proceeds from Issuance of Common Stock

$ 10,588,378

$ 1,847,662

Sale of Stock, Number of Shares Issued in Transaction (in Shares)

1,674,943

625,677

Common Stock [Member] | Maximum [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Shares Issued, Price Per Share (in Dollars per share)

$ 9.08

$ 4.16

Common Stock [Member] | Minimum [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Shares Issued, Price Per Share (in Dollars per share)

$ 2.33

$ 2.59

Common Stock [Member] | Share-based Payment Arrangement, Option [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)

137,958

163,500

Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in Dollars per share)

$ 0.82

Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in Dollars per share)

$ 3.90

$ 1.04

Proceeds from Stock Options Exercised

$ 223,534

$ 121,790

Common Stock [Member] | At Market Issuance Sales Agreement [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Sale of Stock, Consideration Received on Transaction

10,232,857

Sale of Stock, Price Per Share (in Dollars per share)

$ 0.08

Proceeds from Issuance of Common Stock

$ 3,771,048

$ 6,997,935

Sale of Stock, Number of Shares Issued in Transaction (in Shares)

1,674,943

Common Stock [Member] | At Market Issuance Sales Agreement [Member] | Maximum [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Sale of Stock, Consideration Received on Transaction

$ 7,000,000

Sale of Stock, Price Per Share (in Dollars per share)

$ 9.08

Common Stock [Member] | At Market Issuance Sales Agreement [Member] | Minimum [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Sale of Stock, Price Per Share (in Dollars per share)

$ 2.33

Common Stock [Member] | At Market Issuance Sales Agreement [Member] | Registration Rights Agreement [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Proceeds from Issuance of Common Stock

$ 6,817,330

Common Stock [Member] | At Market Issuance Sales Agreement [Member] | Registration Rights Agreement [Member] | Maximum [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Sale of Stock, Consideration Received on Transaction

$ 12,500,000

Preferred Stock [Member] | Common Stock [Member]

SHAREHOLDERS' EQUITY (Details) [Line Items]

Conversion of Stock, Shares Converted (in Shares)

250,000

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity - $ / shares	12 Months Ended
	May 31, 2020	May 31, 2019
Exercise Price Range Per Share $0.71 - $3.90 [Member]
SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]
Options outstanding, number of stock options		1,138,625
Options outstanding, weighted average exercise price		$ 1.65
Exercise Price Range Per Share $2.25 - $3.62 [Member]
SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]
Options granted, number of stock options		558,000
Options granted, weighted average exercise price		$ 2.60
Exercise Price Range Per Share $0.71 - $1.04 [Member]
SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]
Options exercised, number of stock options		(163,500)
Options exercised, weighted average exercise price		$ 0.76
Exercise Price Range Per Share $0.71 - $3.62 [Member]
SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]
Options canceled or expired, number of stock options		(56,916)
Options canceled or expired, weighted average exercise price		$ 2.49
Exercise Price Range Per Share $0.82 - $3.90 [Member]
SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]
Options outstanding, number of stock options	1,476,209
Options outstanding, weighted average exercise price	$ 2.07
Options exercised, number of stock options	(137,958)
Options exercised, weighted average exercise price	$ 1.64
Options outstanding, number of stock options		1,476,209
Options outstanding, weighted average exercise price		$ 2.07
Exercise Price Range Per Share $2.68 - $8.18 [Member]
SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]
Options granted, number of stock options	517,500
Options granted, weighted average exercise price	$ 4.47
Exercise Price Range Per Share $0.85 - $8.18 [Member]
SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]
Options canceled or expired, number of stock options	(66,500)
Options canceled or expired, weighted average exercise price	$ 3.43
Exercise Price Range Per Share $0.82 - $8.18 [Member]
SHAREHOLDERS' EQUITY (Details) - Outstanding Stock Options Activity [Line Items]
Options outstanding, number of stock options
Options outstanding, weighted average exercise price
Options outstanding, number of stock options	1,789,251
Options outstanding, weighted average exercise price	$ 2.75

SHAREHOLDERS' EQUITY (Details_2

SHAREHOLDERS' EQUITY (Details) - Non-vested Stock Options Activity	12 Months Ended
	May 31, 2020$ / sharesshares
Non-vested Stock Options Activity [Abstract]
Non-vested shares, number of shares | shares	769,584
Non-vested shares, weighted average grant date fair value | $ / shares	$ 2.49
Granted, number of shares | shares	517,500
Granted, weighted average grant date fair value | $ / shares	$ 4.47
Vested, number of shares | shares	(407,750)
Vested, weighted average grant date fair value | $ / shares	$ 2.25
Forfeited, number of shares | shares	(56,750)
Forfeited, weighted average grant date fair value | $ / shares	$ 3.55
Non-vested shares, number of shares | shares	822,584
Non-vested shares, weighted average grant date fair value | $ / shares	$ 3.78

SHAREHOLDERS' EQUITY (Details_3

SHAREHOLDERS' EQUITY (Details) - Stock Options Summary	12 Months Ended
	May 31, 2020$ / sharesshares
Range Of Exercise Price $0.82 - $1.04 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Price, Minimum	$ 0.82
Range of Exercise Price, Maximum	$ 1.04
Options Outstanding, Number (in Shares) | shares	276,000
Options Outstanding, Weighted Average Remaining Contractual Life	4 years 160 days
Options Outstanding, Weighted Average Exercise Price	$ 0.84
Options Exercisable, Number (in Shares) | shares	276,000
Options Exercisable, Weighted Average Exercise Price	$ 0.84
Range Of Exercise Price $1.20 - $2.81 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Price, Minimum	1.20
Range of Exercise Price, Maximum	$ 2.81
Options Outstanding, Number (in Shares) | shares	1,072,500
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 208 days
Options Outstanding, Weighted Average Exercise Price	$ 2.17
Options Exercisable, Number (in Shares) | shares	506,000
Options Exercisable, Weighted Average Exercise Price	$ 1.71
Range Of Exercise Price $3.62 - $8.18 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Price, Minimum	3.62
Range of Exercise Price, Maximum	$ 8.18
Options Outstanding, Number (in Shares) | shares	440,751
Options Outstanding, Weighted Average Remaining Contractual Life	7 years 226 days
Options Outstanding, Weighted Average Exercise Price	$ 5.38
Options Exercisable, Number (in Shares) | shares	184,667
Options Exercisable, Weighted Average Exercise Price	$ 3.87

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	May 31, 2020	May 31, 2019
INCOME TAXES (Details) [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%
Deferred Tax Assets, Valuation Allowance	$ 3,175,000	$ 2,459,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	716,000	$ 900,000
Domestic Tax Authority [Member]
INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	9,213,000
California State Income Tax [Member]
INCOME TAXES (Details) [Line Items]
Operating Loss Carryforwards	5,025,000
Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member]
INCOME TAXES (Details) [Line Items]
Tax Credit Carryforward, Amount	438,000
Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]
INCOME TAXES (Details) [Line Items]
Tax Credit Carryforward, Amount	$ 160,000

INCOME TAXES (Details) - Income

INCOME TAXES (Details) - Income tax expense - USD ($)	12 Months Ended
	May 31, 2020	May 31, 2019
Current:
U.S. Federal
Foreign Taxes Subsidiaries	(6,590)	(13,437)
State and local	(800)	(800)
Total current	(7,390)	(14,237)
Deferred:
U.S. Federal		(10,000)
State and local
Total deferred		(10,000)
Income tax expense	$ (7,390)	$ (24,237)

INCOME TAXES (Details) - Inco_2

INCOME TAXES (Details) - Income Tax Rate Reconciliation - USD ($)	12 Months Ended
	May 31, 2020	May 31, 2019
Income Tax Rate Reconciliation [Abstract]
Computed "expected" tax benefit	$ 489,651	$ 497,453
Increase (reduction) in income taxes resulting from:
Change in valuation allowance	(716,000)	(910,000)
State income taxes, net of federal benefit	154,254	89,267
Research and development tax credits	49,770	55,908
Permanent tax differences and other	21,525	(256,572)
Foreign taxes of subsidiaries	(6,590)	(13,437)
Income tax expense	$ (7,390)	$ (24,237)

INCOME TAXES (Details) - Deferr

INCOME TAXES (Details) - Deferred Tax - USD ($)	May 31, 2020	May 31, 2019
Deferred tax assets:
Accounts receivable, principally due to allowance for doubtful accounts	$ 17,000	$ 18,000
Inventory valuation	16,000	12,000
Compensated absences	64,000	48,000
Net operating loss carryforwards	2,286,000	1,735,000
Tax credit carryforwards	599,000	467,000
Deferred rent expense/Capitalized leases	17,000	9,000
Other	171,000	176,000
Accumulated depreciation and amortization	5,000	(6,000)
Total deferred tax assets	3,175,000	2,459,000
Less valuation allowance	(3,175,000)	(2,459,000)
Net deferred tax asset

GEOGRAPHIC INFORMATION (Details

GEOGRAPHIC INFORMATION (Details)	12 Months Ended
	May 31, 2020
Geographic Information Disclosure [Abstract]
Number of Operating Segments	1

GEOGRAPHIC INFORMATION (Detai_2

GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales - USD ($)	12 Months Ended
	May 31, 2020	May 31, 2019
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	$ 6,692,711	$ 5,200,682
Europe [Member]
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	2,434,000	1,694,000
UNITED STATES
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	445,000	523,000
Asia [Member]
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	1,867,000	2,514,000
South America [Member]
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	1,615,000	256,000
Middle East [Member]
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	314,000	214,000
Other Foreign [Member]
GEOGRAPHIC INFORMATION (Details) - Geographic information regarding net sales [Line Items]
Net sales	$ 18,000

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)

May 18, 2020

May 07, 2020

Nov. 30, 2016

May 25, 2016

Jun. 18, 2009

Sep. 30, 2020

May 31, 2019

Dec. 31, 2018

Oct. 31, 2018

Aug. 31, 2020

May 31, 2020

May 31, 2019

May 28, 2020

Dec. 31, 2019

Sep. 25, 2019

Jul. 22, 2019

Jul. 12, 2019

Jan. 31, 2018

Nov. 30, 2017

Sep. 30, 2017

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Research and Development Expense

$ 1,910,209

$ 1,679,098

MEXICO

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Operating Leases, Rent Expense

43,481

46,040

UNITED STATES

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Operating Leases, Rent Expense

300,267

268,550

EZ Detect Product [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Contract Term

12 months

3 years

Other Nonoperating Expense

0

27,579

EZ Detect Product [Member] | Minimum [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Success Fees Percentage

2.50%

EZ Detect Product [Member] | Maximum [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Success Fees Percentage

6.00%

Non-exclusive Distributor Agreement [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Contract Term

2 years

Building In Irvine California [Member] | First Amendment To Lease [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Lease Expiration Date

Aug. 31, 2021

Operating Leases, Rent Expense, Minimum Rentals

$ 21,000

Rental Expense, Increase During Period

23,637

Operating Leases, Rent Expense

22,948

Lease Deposit Liability

$ 22,080

Property Available for Operating Lease [Member] | MEXICO

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

$ 2,926

Operating Leases, Rent Expense

$ 3,239

Lease Expiration Period

10 years

MaxHealth [Member] | EZ Detect Product [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Related Party Transaction, Purchases from Related Party

$ 100,000

Related Party Transaction, Due from (to) Related Party

900,000

900,000

Related Party Transaction, Amounts of Transaction

$ 1,000,000

Related Party Transaction, Description of Transaction

The $1,000,000 was to be used as a prepayment for the first $1,000,000 of purchase orders for the product. While the Company received the first deposit of $100,000, and shipped $100,000 of product to Maxhealth, the Company has not received the second deposit, and has not shipped any further product, which has placed MaxHealth in Default of the agreement

University OF Michigan [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Clinical Trial Agreement Maximum Budgeted Costs

$ 181,015

Research and Development Expense

$ 30,900

40,885

Billed Commitment, Percentage

47.00%

Deaconess Medical Center [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Clinical Trial Agreement Maximum Budgeted Costs

$ 305,000

$ 142,000

Research and Development Expense

141,640

146,760

Research Management Institution [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Clinical Trial Agreement Maximum Budgeted Costs

$ 117,200

Research and Development Expense

13,111

Other Accrued Liabilities, Current

6,670

Biomerica Infoods Product [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Clinical Trial Agreement Maximum Budgeted Costs

$ 107,000

Research and Development Expense

$ 20,875

Billed Commitment, Percentage

19.00%

Accrued Liabilities, Current

$ 2,650

Biomerica Infoods IBS Product [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Clinical Trial Agreement Maximum Budgeted Costs

$ 136,000

Research and Development Expense

$ 45,250

Billed Commitment, Percentage

33.00%

Accrued Liabilities, Current

$ 5,975

Biomerica H. Pylori Product [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Clinical Trial Agreement Maximum Budgeted Costs

$ 57,800

Research and Development Expense

$ 41,845

Billed Commitment, Percentage

72.00%

Houston Methodist Research Institute [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Clinical Trial Agreement Maximum Budgeted Costs

$ 133,000

Research and Development Expense

$ 4,000

Billed Commitment, Percentage

3.00%

Mayo Clinic Arizona [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Clinical Trial Agreement Maximum Budgeted Costs

$ 135,515

Research and Development Expense

$ 17,390

Billed Commitment, Percentage

13.00%

Mayo Clinic Jacksonville [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Clinical Trial Agreement Maximum Budgeted Costs

$ 135,515

Research and Development Expense

$ 17,390

Royalty Agreements [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Royalty Expense

$ 15,000

$ 19,000

Royalty Agreements [Member] | Revenue Benchmark [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Royalty Expense Percentage Of Sales

1.80%

2.90%

Telcon Agreement [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Accrued Fees and Other Revenue Receivable

$ 1,250,000

Stock Issued During Period, Shares, Other (in Shares)

83,333

Proceeds from Fees Received

$ 250,000

Royalty Percentage

15.00%

Mount Sinai License Agreements [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Related Party Transaction, Purchases from Related Party

$ 5,100

Mount Sinai License Agreements [Member] | Subsequent Event [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Related Party Transaction, Purchases from Related Party

$ 2,850

UC License Agreements [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Payments for Other Fees

$ 5,000

License Maintenance Fee, Payable

10,000

UC License Agreements [Member] | Subsequent Event [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Payments for Other Fees

$ 5,000

University Of Southern California [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Accrued Fees and Other Revenue Receivable

17,064

Clinical Trial Agreement Maximum Budgeted Costs

$ 82,472

Research and Development Expense

2,200

Other Research and Development Expense

12,567

University Of Southern California [Member] | Maximum [Member]

COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Research and Development Expense

$ 14,767

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details) - Supplemental cash flow information related to leases	12 Months Ended
	May 31, 2020USD ($)
Supplemental cash flow information related to leases [Abstract]
Operating cash flows from operating leases	$ 311,742
Right-of-use assets obtained in exchange for new operating lease liabilities
Weighted average remaining lease term (in years)	6 years 98 days
Weighted average discount rate	6.50%

COMMITMENTS AND CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Details) - The maturity of lease liabilities	May 31, 2020USD ($)
The maturity of lease liabilities [Abstract]
2021	$ 211,808
2022	236,391
2023	262,810
2024	291,329
2025	322,098
Thereafter	457,051
Total	$ 1,781,487

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - USD ($)	Aug. 27, 2020	Jul. 20, 2020	Jul. 13, 2020	Jun. 15, 2020	Aug. 31, 2020	Jun. 25, 2020
University Of Texas Health Science Center [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Clinical Trial Agreement Maximum Budgeted Costs						$ 139,850
Share-based Payment Arrangement, Option [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					12,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price					$ 1.20
Proceeds from Stock Options Exercised					$ 14,900
Share-based Payment Arrangement, Option [Member] | Employees [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				52,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 5.46
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Payment Arrangement, Option [Member] | Employees and Consultants [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			76,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 8.70
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Payment Arrangement, Option [Member] | Consultant [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,500		7,500
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 7.47		$ 8.70
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years		10 years
Share-based Payment Arrangement, Option [Member] | Employee and Board Member [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	33,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 7.47
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Common Stock [Member] | Maximum [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Proceeds from Issuance of Common Stock		$ 90,000,000